Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer

Li, Xiaoxian; Wetherilt, Ceyda Sönmez; Krishnamurti, Uma; Yang, Jing; Ma, Yanhui; Styblo, Toncred M.; Meisel, Jane L.; Peng, Limin; Siddiqui, Momin T.; Cohen, Cynthia; Aneja, Ritu

doi:10.1093/ajcp/aqw134

Cited by 83 publications

(51 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, PD‐L1 expression has been positively and independently associated with DFS/RFS and/or OS in several unselected primary BC cohorts . In addition, when considering specific BC subtypes, it has been suggested that PD‐L1 protein expression may retain a positive prognostic role in TNBC and in HER2+ BC, in both trastuzumab‐treated and untreated patients .…”

Section: Methodsmentioning

confidence: 99%

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple‐negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this appealing treatment strategy. In this context, the role of programmed cell death ligand 1 (PD‐L1) as a potential prognostic and/or predictive biomarker has been intensively explored, with controversial results. The aim of the present review is to collect available evidence on the biological relevance and clinical utility of PD‐L1 expression in BC, with particular emphasis on technical aspects, prognostic implications, and predictive value of this promising biomarker. Implications for Practice In the light of the promising results coming from trials of immune checkpoint inhibitors for breast cancer treatment, the potential predictive and/or prognostic role of programmed cell death ligand 1 (PD‐L1) in breast cancer has gained increasing interest. This review provides clinicians with an overview of the available clinical evidence regarding PD‐L1 as a biomarker in breast cancer, focusing on both data with a possible direct impact on clinic and methodological pitfalls that need to be addressed in order to optimize PD‐L1 implementation as a clinically useful tool for breast cancer management.

show abstract

Section: Methodsmentioning

confidence: 99%

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

2019

View full text Add to dashboard Cite

show abstract

“…Stromal cells express the immune-checkpoint protein programmed cell death 1 ligand 1 (PD-L1). The effect of stromal PDL1 expression on immunotherapy outcomes is currently unclear, with some studies showing an association with a better prognosis for patients with breast cancer 269 , but also a poor prognosis for patients with adult T-cell leukaemia 270 .…”

Section: Effects Of Tumour Stroma On Therapymentioning

confidence: 99%

Targeting the tumour stroma to improve cancer therapy

2018

View full text Add to dashboard Cite

Cancers are not merely composed of cancer cells alone and, instead, are complex ‘ecosystems’ comprising many different cell types and noncellular factors. The tumour stroma is a critical component of the tumour microenvironment, where it has crucial roles in tumour initiation, progression, and metastasis. Most anticancer therapies target cancer cells specifically, but the tumour stroma can promote resistance of cancer cells to such therapies, eventually resulting in fatal disease. Therefore, novel treatment strategies should combine anticancer and antistroma agents. Herein, we provide an overview of the advances in understanding the complex cancer cell–tumour stroma interactions, and discuss how this knowledge can result in more effective therapeutic strategies, which might ultimately improve patient outcomes.

show abstract

“…Although the PD-L1 expression on TILs has not yet been thoroughly examined in the literature, it seems from the existing studies that it is of great prognostic value (61). From these studies PDL1IC expression has shown to have opposite prognostic value compared to PDL1TC expression, since most cases are related to higher DFS, RFS as well as OS (41,62). Zhao et al (61) studied the prognostic value of PDL1IC expression on several solid tumors, and indicated that it is a positive prognostic factor, especially in IBC.…”

Section: Figure 1 (A) Pd-l1 Expression In Tumor Cells (×20) (B) Pd-mentioning

confidence: 99%

PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old

Evangelou

Papoudou‐Bai

Karpathiou

et al. 2020

In Vivo

View full text Add to dashboard Cite

Background/Aim: To evaluate the association between programmed cell death ligand 1 (PD-L1) expression on both tumor cells (TC) and inflammatory cells (IC), tumor infiltrating lymphocytes (TILs), CD3 + and CD8 + lymphocytes and other clinicopathological parameters in primary infiltrative breast cancer (IBC) of young women, a population shown to have a worse prognosis. Materials andMethods: A retrospective study was performed collecting data from patients younger than 40 years old. Forty-five young women with IBC were included. Whole tissue sections were used to evaluate all parameters. Results: Twenty percent (20%) of cases showed PD-L1 expression by tumor cells (PDL1TC) and 44.4% showed PD-L1 expression by immune cells (PDL1IC). Furthermore, 28.88% revealed high stromal TILs. PDL1TC and PDL1IC expression were significantly associated with tumor diameter and expression of estrogen (ER) and progesterone (PR) receptors and Ki67. PDL1TC expression was also associated with grade. High TILs were associated with tumor diameter, ER and Ki67 expression. PDL1TC, PDL1IC expression and TILs were associated with the density of CD3 + and CD8 + lymphocytes. Conclusion: Our results are similar to those of other age groups, as reported in the literature.

show abstract

Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer

Abstract: PD-L1 expression is seen in a high proportion of TNBCs and associated with better DFS.

Cited by 83 publications

References 29 publications

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value

Targeting the tumour stroma to improve cancer therapy

PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old

Contact Info

Product

Resources

About